- Home
- SAIH vs AIM Comparison
SAIH vs AIM Comparison
Compare SAIH & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAIH
- AIM
- Stock Information
- Founded
- SAIH 2019
- AIM 1966
- Country
- SAIH Singapore
- AIM United States
- Employees
- SAIH N/A
- AIM N/A
- Industry
- SAIH
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAIH
- AIM Health Care
- Exchange
- SAIH NYSE
- AIM Nasdaq
- Market Cap
- SAIH 17.5M
- AIM 16.6M
- IPO Year
- SAIH N/A
- AIM N/A
- Fundamental
- Price
- SAIH $0.85
- AIM $0.26
- Analyst Decision
- SAIH
- AIM Strong Buy
- Analyst Count
- SAIH 0
- AIM 1
- Target Price
- SAIH N/A
- AIM $5.00
- AVG Volume (30 Days)
- SAIH 1.9M
- AIM 384.9K
- Earning Date
- SAIH 11-11-2024
- AIM 11-13-2024
- Dividend Yield
- SAIH N/A
- AIM N/A
- EPS Growth
- SAIH N/A
- AIM N/A
- EPS
- SAIH N/A
- AIM N/A
- Revenue
- SAIH $6,776,000.00
- AIM $201,000.00
- Revenue This Year
- SAIH N/A
- AIM N/A
- Revenue Next Year
- SAIH N/A
- AIM N/A
- P/E Ratio
- SAIH N/A
- AIM N/A
- Revenue Growth
- SAIH N/A
- AIM 19.64
- 52 Week Low
- SAIH $0.54
- AIM $0.21
- 52 Week High
- SAIH $1.80
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- SAIH N/A
- AIM 42.56
- Support Level
- SAIH N/A
- AIM $0.24
- Resistance Level
- SAIH N/A
- AIM $0.29
- Average True Range (ATR)
- SAIH 0.00
- AIM 0.02
- MACD
- SAIH 0.00
- AIM 0.00
- Stochastic Oscillator
- SAIH 0.00
- AIM 48.33
About SAIH SAIHEAT LIMITED
SAI.TECH Global Corp is an energy-saving mining operator that engages in the hosting of Bitcoin mining machines for its clients. It uses a proprietary liquid cooling and heat exchange technology towards mining machines that enables the utilization of waste heat to provide recycled energy heating for potential customers while achieving lower mining operating costs. The Company has four reportable segments namely equipment sales, hosting, mining pool business, and mining.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.